What Ferozsons Laboratories does

Ferozsons Laboratories Limited is a Pakistan-headquartered, publicly listed pharmaceutical company (PSX ticker FEROZ) founded in 1954 with manufacturing operations beginning in 1956. The company produces and markets more than 140 branded generic pharmaceutical products across 12+ therapeutic areas, including cardiology, hepatology, gastroenterology, oncology, diabetes, antivirals, and antibiotics, manufactured at a cGMP-compliant facility in Nowshera (Khyber Pakhtunkhwa) certified to ISO, ICH, WHO, and PIC/S standards. Revenue is generated through four streams: domestic pharmaceutical sales, international exports to 30+ countries across Asia, Africa, Europe, South America, and Central America, contract manufacturing for global pharmaceutical companies (historically including Boots UK, Grunenthal, and Procter & Gamble), and medical-device distribution through partnerships with Boston Scientific, Nihon Kohden, GE Healthcare, and Butterfly Network.

The business model combines first-party branded generics with royalty-free voluntary licensing for breakthrough therapies from Gilead Sciences, including Sovaldi (sofosbuvir for hepatitis C), Remedia (remdesivir for COVID-19), and Yeztugo (lenacapavir for HIV PrEP), the last of which covers 120 high-incidence resource-limited countries. Biopharmaceutical capability is housed in BF Biosciences Limited, a joint venture with Argentina's Bagó Group established in 2006, which operates Pakistan's only cGMP-compliant biotech facility and was separately listed on the Pakistan Stock Exchange in 2024. Through this subsidiary, Ferozsons launched Sematide (semaglutide) in 2024 and Zeptide (tirzepatide) in 2025, marking entry into the GLP-1 therapeutic class for diabetes and obesity.

FY2025 reported net sales of PKR 13.858 billion (approximately USD 45-50 million), up 9% year-over-year, with net profit of PKR 528.243 million and gross margin of 41.27%, following a margin-compressed 2023. The company is led by CEO Osman Khalid Waheed, with Amna Piracha Khan as Chairperson of the Board, and operates from corporate headquarters in Lahore with a registered office in Rawalpindi and the Nowshera manufacturing site.

Name

Ferozsons Laboratories

Legal name

Ferozsons Laboratories Limited

Website

https://ferozsons-labs.com

Company type

Public

Founded year

1954

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Ferozsons Laboratories is a publicly listed Pakistani pharmaceutical company (PSX: FEROZ) that manufactures and distributes 140+ branded generics, in-licensed breakthrough therapies from Gilead Sciences, and advanced medical devices through global partnerships, serving patients in Pakistan and 30+ export markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Biotechnology products
• Medical device distribution
• Hepatitis treatments

Headquarters

HQ city

Lahore

HQ country

Pakistan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Sales (Domestic): Sale of branded generic pharmaceutical products across multiple therapeutic areas including cardiology, hepatology, gastroenterology, oncology, antivirals, antibiotics, and diabetes treatments. Net sales reached Rs.13,857.967 million in FY2025 with gross margin of 41.27%.
2. Licensed Products (Gilead Partnership): Manufacturing and distribution of in-licensed products from Gilead Sciences including Sovaldi (sofosbuvir) for Hepatitis C, Remedia (remdesivir) for COVID-19, and Yeztugo (lenacapavir) for HIV prevention. Royalty-free voluntary licensing for 120 high-incidence countries.
3. Contract Manufacturing: cGMP-compliant manufacturing services for international pharmaceutical companies. Past clients include Boots UK, Grunenthal Germany, Lakeside Laboratories, and Procter & Gamble (Vicks VapoRub).
4. Medical Devices Distribution: Distribution of advanced medical technologies including Boston Scientific interventional devices (cardiology, GI endoscopy, oncology, urology), Nihon Kohden patient monitoring and diagnostic systems, and Butterfly Network handheld ultrasound technology.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Ferozsons Laboratories is a pharmaceutical manufacturer that develops, produces, and sells more than 140 branded generic medicines across therapeutic areas including oncology, cardiology, hepatology, gastroenterology, antidiabetics, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief. The company also distributes advanced medical devices through global partnerships and operates cGMP-compliant contract manufacturing services for international pharmaceutical clients. Its subsidiary BF Biosciences manufactures biopharmaceuticals such as Sematide and Zeptide.

Product overview

Ferozsons Laboratories Limited operates as a patient-centric pharmaceutical company offering a broad portfolio of more than 140 pharmaceutical products across 12+ therapeutic areas (oncology, cardiology, hepatology, gastroenterology, antidiabetics, weight management, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief). The company operates through two divisions: Pharmaceuticals (branded generics and in-licensed products) and Medical Technologies (distribution of advanced medical devices through global partnerships). Key pharmaceutical brands include Sovaldi (Hepatitis C), Remedia (COVID-19), and DiaresQ (childhood diarrhea). Subsidiary BF Biosciences Limited focuses on biopharmaceuticals including Zeptide (Tirzepatide) and Sematide (Semaglutide) for diabetes and obesity. Medical Technologies division distributes Boston Scientific interventional devices, Nihon Kohden diagnostic/monitoring systems, and Butterfly Network handheld ultrasound devices. The company also offers cGMP-compliant contract manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

• Remedia: Remdesivir product launched for COVID-19 treatment under voluntary licensing partnership with Gilead
• Zeptide
• Sematide
• Sovaldi

Products and services

• Zeptide (Tirzepatide) An innovative tirzepatide treatment for Type 2 diabetes and obesity, manufactured and launched in Pakistan by BF Biosciences Limited (Ferozsons' biopharmaceutical joint venture with Bagó Group of Argentina). Targeted at patients needing advanced metabolic disease therapy.
• Sematide (Semaglutide) Pakistan's first locally manufactured GLP-1 semaglutide therapy for diabetes, produced by BF Biosciences Limited. Targeted at patients requiring advanced GLP-1 therapy in Pakistan.
• Remedia (Remdesivir) Remdesivir COVID-19 treatment manufactured under voluntary licensing partnership with Gilead Sciences for severe COVID-19 in hospitalized patients, also exported internationally.
• Sovaldi (sofosbuvir) Sofosbuvir breakthrough direct-acting antiviral therapy for Hepatitis C introduced in Pakistan under a dedicated patient access program through partnership with Gilead Sciences.
• DiaresQ Innovative nutritional product for childhood diarrhea, exclusively marketed in Pakistan through partnership with PanTheryx Inc., USA. Targeted at pediatric patients and caregivers.
• Branded Generic Pharmaceutical Portfolio (140+ products) Broad portfolio of more than 140 branded generic pharmaceutical products covering oncology, cardiology, hepatology, gastroenterology, antidiabetics, weight management, antivirals, antibiotics, pulmonology, psychiatry, dermatology, urology, and pain relief. Targeted at healthcare providers and patients across Pakistan and 30+ export markets.
• Farapulse PFA System Pulsed Field Ablation system developed by Boston Scientific for treatment of atrial fibrillation, introduced in Pakistan through Ferozsons' distribution partnership. Targeted at cardiology departments and electrophysiologists treating atrial fibrillation.
• Boston Scientific Medical Devices Distribution Authorized distribution in Pakistan of Boston Scientific interventional medical devices across cardiology, gastrointestinal endoscopy, oncology, peripheral vascular disease, urology, and women's health. Targeted at Pakistani healthcare providers and hospitals.
• Nihon Kohden Medical Technologies Distribution Authorized distribution in Pakistan of Nihon Kohden advanced diagnostic and patient monitoring systems including patient monitoring, neurology and EEG diagnostics, cardiology and ECG systems, and critical care monitoring. Targeted at Pakistani hospitals.
• Butterfly Network Handheld Ultrasound Distribution Authorized distribution in Pakistan of Butterfly Network handheld ultrasound technology and AI-enabled digital medical imaging solutions with applications in emergency medicine, critical care, obstetrics, and primary care. Targeted at Pakistani healthcare providers.
• Contract Manufacturing Services cGMP-compliant pharmaceutical manufacturing services with capacity for tablets (550M annually), capsules (222M), dry suspensions (2.5M bottles), ointments/creams (11M tubes), sachets (11M), ampoules, vials, pre-filled syringes, and lyophilized products. Past clients include Boots UK, Grunenthal Germany, Lakeside Laboratories, and Procter & Gamble. Targeted at international pharmaceutical and consumer health companies outsourcing production.

Quantifiable outcome

• Over 250,000 hepatitis C patients cured nationwide through Sovaldi access program
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core, supporting and flagship.

• Nihon KohdencoreChannel Partner/ Reseller/ Distributor · 1 January 2022Distribution partnership for advanced diagnostic and patient monitoring systems. Technologies include patient monitoring systems, neurology and EEG diagnostics, cardiology and ECG systems, and critical care monitoring technologies for hospitals and healthcare facilities across Pakistan.
• PanTheryxsupportingChannel Partner/ Reseller/ Distributor · 1 January 2017Exclusive marketing partnership for DiaresQ, an innovative nutritional product for childhood diarrhea. Product recognized in Innovations 2030 Countdown Report by PATH, USAID, and NORAD.
• GE HealthcarecoreChannel Partner/ Reseller/ Distributor · 1 January 2016Channel partnership for marketing and sale of value-segment medical devices in Pakistan, expanding medical technology portfolio beyond pharmaceutical products.
• BioGaiasupportingChannel Partner/ Reseller/ Distributor · 1 January 2012Partnership to introduce world's leading premium Swedish probiotics in Pakistan, expanding product portfolio in nutritional and digestive health category.
• Boston ScientificcoreChannel Partner/ Reseller/ Distributor · 1 January 2008Authorized distributor in Pakistan for Boston Scientific medical devices since 2008. Partnership covers advanced interventional technologies in cardiology, gastrointestinal endoscopy, oncology, peripheral vascular disease, urology, and women's health. Ferozsons introduced Pakistan's first public-sector Pulsed Field Ablation programme at PIMS using the Farapulse PFA System.
• Bagó GroupflagshipStrategic or Co-development Partner · 1 January 2006Joint venture established in 2006 to create BF Biosciences Limited, Pakistan's first biopharmaceutical company. cGMP-compliant biotechnology facility dedicated to manufacture of biological products. BF Biosciences successfully listed on PSX in 2024 following IPO. Strategic partnership also includes import and marketing of biological products in oncology and liver disease.
• Curatis Pharma GmbHsupportingChannel Partner/ Reseller/ Distributor · 1 January 2002Strategic partnership for import and marketing of biological products in oncology and liver disease from Germany.
• Gilead SciencesflagshipStrategic or Co-development PartnerRoyalty-free voluntary licensing partnership for manufacture and distribution of lenacapavir (HIV PrEP), sofosbuvir/Sovaldi (Hepatitis C), and remdesivir/Remedia (COVID-19) in 120 high-incidence resource-limited countries. Ferozsons is one of six generic partners including Dr. Reddy's, Emcure, Eva Pharma, Hetero, and Mylan. The partnership enabled introduction of breakthrough therapies in Pakistan including first direct-acting antiviral for Hepatitis C.
• Butterfly NetworkcoreChannel Partner/ Reseller/ DistributorAuthorized distributor in Pakistan for Butterfly Network handheld ultrasound technology and digital medical imaging. Enables introduction of AI-enabled portable ultrasound solutions to healthcare providers across Pakistan with applications in emergency medicine, critical care, obstetrics, and primary care.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Dr. Reddy's Laboratories: Indian-headquartered global generic and biopharmaceutical company with a similar voluntary licensing-led model for breakthrough antivirals (also a Gilead licensee). Comparable in licensed generics strategy, biopharma ambitions, and emerging markets export focus.
• Hetero Labs: Indian-headquartered global generics manufacturer and one of the six Gilead voluntary licensees for Sovaldi, Remdesivir, and lenacapavir. Directly comparable in licensed antiviral manufacturing model and emerging markets supply footprint.

Direct peers

• Searle Pakistan: Listed Pakistani pharmaceutical company offering branded generics and licensed products across similar therapeutic categories. Directly comparable in business model, regulatory standing, and Pakistan Stock Exchange listing.
• Hilton Pharma: Karachi-based Pakistani pharmaceutical manufacturer with a comparable branded generics and licensing-led business model. Closely comparable in product breadth, domestic sales motion, and therapeutic area coverage.
• Sami Pharmaceuticals: Pakistani pharmaceutical company operating in branded generics across multiple therapeutic areas including cardiology and gastroenterology. Directly comparable mid-sized domestic peer.
• Getz Pharma: One of Pakistan's largest domestic pharmaceutical manufacturers with a broad branded generics portfolio across multiple therapeutic areas. Highly comparable in product mix, domestic market positioning, and export ambitions to Ferozsons.

Broad incumbents

• Abbott Laboratories Pakistan: Multinational pharmaceutical incumbent with established Pakistan presence across branded generics and nutrition. Comparable as a competitor in the same therapeutic categories, though with broader global portfolio backing.
• Bayer Pakistan: Multinational pharmaceutical and consumer health incumbent with Pakistan operations spanning cardiology, women's health, and specialty. Comparable as an established incumbent with overlapping product categories.
• GlaxoSmithKline Pakistan: Listed Pakistani subsidiary of GSK offering vaccines, specialty, and general medicines. Comparable as a broad incumbent competing for the same prescriber base and therapeutic franchises.

Regional players

• CCL Pharmaceuticals: Pakistani pharmaceutical manufacturer with broad branded generics portfolio. Comparable mid-cap domestic peer with overlapping therapeutic categories and similar Pakistan PSX listing structure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/FerozsonsLabs
• YouTubeyoutube.com/channel/UCFerozsonsLabs
• Facebookfacebook.com/ferozsonslabs
• LinkedInlinkedin.com/company/ferozsons-laboratories-limited
• Instagraminstagram.com/ferozsonslabs

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ferozsons Laboratories